SHENZHEN WEIGUANG BIOLOGICAL PRODUCTS CO., LTD. Financials Shenzhen Weiguang Biological Products Co., Ltd.
Equities
002880
CNE100002Q58
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.8 CNY | -5.20% |
|
+9.22% | -6.63% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7,781 | 7,298 | 7,233 | 7,439 | 7,439 | - |
| Enterprise Value (EV) 1 | 7,781 | 7,298 | 7,233 | 7,967 | 7,439 | 7,439 |
| P/E ratio | 40.9 x | 35.5 x | 61.6 x | 36.4 x | 29 x | 25.2 x |
| Yield | 0.52% | - | - | - | - | - |
| Capitalization / Revenue | 8.6 x | - | - | 7.6 x | 6.23 x | 5.52 x |
| EV / Revenue | 8.6 x | - | - | 7.6 x | 6.23 x | 5.52 x |
| EV / EBITDA | - | - | - | 23.7 x | 20.7 x | 18.5 x |
| EV / FCF | - | - | - | 115 x | - | - |
| FCF Yield | - | - | - | 0.87% | - | - |
| Price to Book | 4.85 x | - | - | 3.96 x | 3.34 x | 3.05 x |
| Nbr of stocks (in thousands) | 226,800 | 226,800 | 226,800 | 226,800 | 226,800 | - |
| Reference price 2 | 34.31 | 32.18 | 31.89 | 32.80 | 32.80 | 32.80 |
| Announcement Date | 4/14/21 | 4/14/22 | 4/25/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 904.6 | - | - | 1,049 | 1,194 | 1,347 |
| EBITDA 1 | - | - | - | 335.7 | 359 | 402 |
| EBIT 1 | 220.6 | - | - | 247.3 | 300 | 346 |
| Operating Margin | 24.39% | - | - | 23.59% | 25.13% | 25.69% |
| Earnings before Tax (EBT) 1 | 219 | - | - | 245.5 | 299 | 344 |
| Net income 1 | 190.4 | 205.4 | 117.4 | 218.7 | 255 | 294 |
| Net margin | 21.05% | - | - | 20.85% | 21.36% | 21.83% |
| EPS 2 | 0.8395 | 0.9058 | 0.5178 | 0.9641 | 1.130 | 1.300 |
| Free Cash Flow 1 | - | - | - | 69.16 | - | - |
| FCF margin | - | - | - | 6.6% | - | - |
| FCF Conversion (EBITDA) | - | - | - | 20.6% | - | - |
| FCF Conversion (Net income) | - | - | - | 31.63% | - | - |
| Dividend per Share | 0.1786 | - | - | - | - | - |
| Announcement Date | 4/14/21 | 4/14/22 | 4/25/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | 69.2 | - | - |
| ROE (net income / shareholders' equity) | 12.5% | - | - | 11.4% | 11.5% | 12% |
| ROA (Net income/ Total Assets) | 11.1% | - | - | 7.4% | 8% | 8.5% |
| Assets 1 | 1,711 | - | - | 3,181 | 3,188 | 3,459 |
| Book Value Per Share 2 | 7.070 | - | - | 8.880 | 9.810 | 10.80 |
| Cash Flow per Share | 1.340 | - | - | - | - | - |
| Capex 1 | 189 | - | - | 329 | 216 | 159 |
| Capex / Sales | 20.85% | - | - | 31.36% | 18.09% | 11.8% |
| Announcement Date | 4/14/21 | 4/14/22 | 4/25/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
32.8
CNY
Average target price
36
CNY
Spread / Average Target
+9.76%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.63% | 1.03B | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
- Stock Market
- Equities
- 002880 Stock
- Financials Shenzhen Weiguang Biological Products Co., Ltd.